We also found numerical differences between high-CD4 and pathological response according to MP in the breast, in the entire cohort (responders high-CD4: 19/47, 40.4% vs. low-CD4: 12/53, 22.6%; p = 0.055), and in luminal-B tumours (responders high-CD4: 9/19, 47.4% vs. low-CD4: 5/25, 20%; p = 0.054). This evidence concerns the gene CD4 and neoplasm.